You are here: Industry Insights > I-SPY COVID

News List

NRx Pharmaceuticals and Quantum Leap With Treatment of Severely Ill COVID-19 Patients with ZYESAMIÔ americanpharmaceuticalreview
July 14, 2021
NRx Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative™ have begun treating patients with inhaled ZYESAMIÔ (Aviptadil), in the I-SPY COVID Trial (NCT04488081), a phase 2 adaptive platform trial aimed at improving treatment for severely ...
QLHC Concludes Apremilast Not Likely to Reduce Time to COVID Recovery, Mortality americanpharmaceuticalreview
March 22, 2021
Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, announced that apremilast (Otezla), made by Amgen, has been dropped for futility.
Quantum Leap Healthcare Discontinues Razuprotafib I-SPY COVID Trial americanpharmaceuticalreview
March 11, 2021
Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, will not proceed with further testing of the Aerpio drug, razuprotafib.
COVID R&D Alliance, Quantum Leap Healthcare Collaborative Enroll First Patients in COVID Trial americanpharmaceuticalreview
August 11, 2020
Members of the COVID R&D Alliance AbbVie, Amgen, and Takeda Pharmaceutical announced the first patients enrolled in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and ...
AbbVie, Amgen and Takeda jointly study impact of anti-inflammatory drugs in COVID-19 treatment expresspharma
August 04, 2020
I-SPY COVID will evaluate the impact of cenicriviroc, Otezla, and Firazyr on inflammatory response in severely ill, hospitalised COVID-19 patients.